Log in

Relevant bibliographies by topics / Acute Leukaemia - Treatment

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Acute Leukaemia - Treatment'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Acute Leukaemia - Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Acute Leukaemia - Treatment"

1

Kuzmits, Rudolf, Paul Aiginger, Matthias M. Müller, Günter Steurer, and Werner Linkesch. "Assessment of the sensitivity of leukaemic cells to cytotoxic drugs by bioluminescence measurement of ATP in cultured cells." Clinical Science 71, no. 1 (July 1, 1986): 81–88. http://dx.doi.org/10.1042/cs0710081.

Full text

Abstract:

1. A short-term test in vitro is described, which can be used to detect resistance to cytostatic agents in leukaemic cells. Leukaemic cell suspensions were incubated with cytostatic agents and the resulting intracellular ATP concentrations were measured by a bioluminescence ATP assay. 2. There was a clear dose-effect relationship in acute leukaemia and chronic lymphocytic leukaemia cells for drugs used in the treatment of leukaemias. A good correlation was found between the ATP content of leukaemic cells and cell viability as determined by the trypan blue dye exclusion test. 3. Preliminary ind

APA, Harvard, Vancouver, ISO, and other styles

2

Ivanovic, Mirjana, Olivera Jovicic, Jelena Mandic, Dusko Bogetic, and Marcello Maddalone. "Oral manifestations of acute leukaemia." Srpski arhiv za celokupno lekarstvo 139, no. 1-2 (2011): 103–6. http://dx.doi.org/10.2298/sarh1102103i.

Full text

Abstract:

Acute leukaemia is the most common form of chilhood cancer. The aim of this paper was to underline the importance of oral manifestations in children with acute leukaemia. The disease and its treatment can directly or indirectly affect oral health. Oral manifestations are gingival inflammation and enlargement. Leukaemic cells are capable of infiltrating the gingiva and the deeper periodontal tissues which leads to ulceration and infection of oral tissues. Gingival bleeding is a common sign in patients with leukaemia. Symptoms include local lymphadenopathy, mucous membrane Petechiae and ecchymos

APA, Harvard, Vancouver, ISO, and other styles

3

Skarsgård, Lisa Stenman, Mattias K. Andersson, Marta Persson, Ann-Cathrine Larsen, Sarah E. Coupland, Göran Stenman, and Steffen Heegaard. "Clinical and genomic features of adult and paediatric acute leukaemias with ophthalmic manifestations." BMJ Open Ophthalmology 4, no. 1 (October 2019): e000362. http://dx.doi.org/10.1136/bmjophth-2019-000362.

Full text

Abstract:

ObjectiveTo describe the clinicopathological and genomic features of nine patients with primary and secondary orbital/ocular manifestations of leukaemia.MethodsAll orbital/ocular leukaemic specimens from 1980 to 2009 were collected from the Danish Register of Pathology. In six cases, medical records and formalin-fixed, paraffin-embedded blocks were available. Three cases from the Department of Pathology, Royal Liverpool University Hospital, were also included. Immunophenotypes and MYB oncoprotein expression were ascertained by immunohistochemistry. Genomic imbalances were analysed with compara

APA, Harvard, Vancouver, ISO, and other styles

4

Arruda, Walter Oleschko, María Belén Montú, Marcelo de Souza R. de Oliveira, and Ricardo Ramina. "Acute myeloid leukaemia induced by mitoxantrone: case report." Arquivos de Neuro-Psiquiatria 63, no. 2a (June 2005): 327–29. http://dx.doi.org/10.1590/s0004-282x2005000200024.

Full text

Abstract:

Mitoxantrone (MX) is an immunosupressant drug used in secondarily progressive multiple sclerosis (SPMS) and in relapsing-remitting multiple sclerosis (RRMS). It has a leukemogenesis potential induced by cytogenetic abnormalities, though with a low incidence. Promyelocitic leukaemia (type M3) and other forms of acute myeloblastic leukaemias (M4 and M5) have been described in a few MS patients who received MX during their treatment. We describe a white female patient, 47 year-old, with SPMS (EDSS = 4) with 14 years of disease. She received MX during her disease and developed acute promyelocytic

APA, Harvard, Vancouver, ISO, and other styles

5

Bhalla, Amit. "Clofarabine: a next-generation deoxyadenosine analogue." International Journal of Basic & Clinical Pharmacology 7, no. 5 (April 23, 2018): 1048. http://dx.doi.org/10.18203/2319-2003.ijbcp20181660.

Full text

Abstract:

Acute lymphoblastic leukaemia (ALL) is the most common of the paediatric leukaemias. It is estimated that the use of modern combination chemotherapy results in long-term remission in nearly 80% of children diagnosed with ALL. Despite therapy advances, approximately 20% of children with ALL, experience leukaemia relapse. Clofarabine (2-chloro-2’-fluoro-2’-deoxy-9-β-D-arabinofuranosyladenine) is a second-generation nucleoside analogue and is structurally related to fludarabine and cladribine which are widely used in the treatment of lymphoproliferative disorders. Clofarabine exhibits greater aff

APA, Harvard, Vancouver, ISO, and other styles

6

Burnett, Alan K. "Treatment of acute myeloid leukaemia." Clinical Medicine 13, Suppl 6 (December 2013): s58—s61. http://dx.doi.org/10.7861/clinmedicine.13-6-s58.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Apostolidou, Effrosyni, Ronan Swords, Yesid Alvarado, and Francis J. Giles. "Treatment of Acute Lymphoblastic Leukaemia." Drugs 67, no. 15 (2007): 2153–71. http://dx.doi.org/10.2165/00003495-200767150-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

LÖWENBERG, B. "Treatment of acute myelogenous leukaemia." Journal of Internal Medicine 242 (July 1997): 17–22. http://dx.doi.org/10.1111/joim.1997.242.s740.17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Omura, GeorgeA. ""MAINTENANCE TREATMENT" FOR ACUTE LEUKAEMIA." Lancet 328, no. 8516 (November 1986): 1154. http://dx.doi.org/10.1016/s0140-6736(86)90553-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Burnett, AK, and OB Eden. "The treatment of acute leukaemia." Lancet 349, no. 9047 (January 1997): 270–75. http://dx.doi.org/10.1016/s0140-6736(96)08086-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Acute Leukaemia - Treatment"

1

Thornton, Nadia. "L-alanosine : selective treatment in relapsed childhood acute lymphoblastic leukaemia." Thesis, University of Newcastle Upon Tyne, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.440588.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Johnson, Peter R. E. "The biology and treatment of acute myeloid leukaemia in elderly patients." Thesis, University of Aberdeen, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306856.

Full text

Abstract:

Acute myeloid leukaemia (AML) is predominantly a disease of the elderly; the median age is 64 years and almost 60% of cases are over 60 years old. Unfortunately however, the treatment of AML in elderly patients is generally unsatisfactory with significantly poorer remission rates and overall survival than in younger patients. We have designed a novel treatment regimen consisting of Mitozantrone and Cytosine Arabinoside specifically for elderly patients and have evaluated the regimen in 104 patients over 60 years old in the North West region. The complete remission rate was 58%, the median dura

APA, Harvard, Vancouver, ISO, and other styles

3

Lehtinen, S. (Satu). "Neurotoxicity in children after treatment for acute lymphoblastic leukaemia and methotrexate neurotoxicity in a controlled animal model." Doctoral thesis, University of Oulu, 2003. http://urn.fi/urn:isbn:9514270339.

Full text

Abstract:

Abstract In the Nordic countries, event-free survival (EFS) exceeds 80% in certain groups of children treated for acute lymphoblastic leukaemia (ALL). With the improved cure rates, however, there are more children suffering from neurological late effects, especially due to therapy directed at the central nervous system (CNS). The aim of this study is to examine the changes taking place in the nervous system after leukemia treatment and to evaluate the role of treatment in these changes in patients and in an animal model. Twenty-seven ALL survivors and healthy controls were examined by means o

APA, Harvard, Vancouver, ISO, and other styles

4

Hallböök, Helene. "Acute lymphoblastic leukaemia in adult patients : studies of prognostic factors, treatment results and in vitro cellular drug resistance /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5768.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hallböök, Helene. "Acute Lymphoblastic Leukaemia in Adult Patients : Studies of Prognostic Factors, Treatment Results and in vitro Cellular Drug Resistance." Doctoral thesis, Uppsala University, Department of Medical Sciences, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5768.

Full text

Abstract:

<p>Treatment results and clinical characteristics in adult acute lymphoblastic leukaemia (ALL) were evaluated regarding three issues: a new treatment with cytarabine up-front, stem cell transplantation and a comparison between adult and paediatric treatment protocols. All studies were conducted on a national basis. Furthermore, activity of imatinib was investigated by in vitro cytotoxicity assay. </p><p>The national protocol was evaluated in 153 adult ALL patients. A high complete remission rate, 86%, was achieved with 29% overall survival at 3-years. Favourable outcome was identified in patie

APA, Harvard, Vancouver, ISO, and other styles

6

Krishnan, Shekhar. "In vitro evaluation of asparagine endopeptidase as a candidate biomarker of treatment failure in childhood acute lymphoblastic leukaemia." Thesis, Queen Mary, University of London, 2011. http://qmro.qmul.ac.uk/xmlui/handle/123456789/1294.

Full text

Abstract:

Background Although cure rates in childhood acute lymphoblastic leukaemia (ALL) approach 90%, relapses, particularly central nervous system (CNS) relapses, pose a significant therapeutic challenge. Prevention of relapses requires better predictive biomarkers. Towards this end, global gene-expression microarray screens of primary ALL samples were performed. Overexpression of the lysosomal cysteine protease, asparagine endopeptidase (AEP) was identified in adverse-risk progenitor-B ALL genotypes. AEP overexpression in adult human epithelial cancers has been linked to metastasis and adverse progn

APA, Harvard, Vancouver, ISO, and other styles

7

Liem, Natalia Women's &amp Children's Health Faculty of Medicine UNSW. "The development of an in vivo model to study the biology and treatment of childhood acute lymphoblastic leukaemia (ALL)." Awarded by:University of New South Wales. Women's & Children's Health, 2007. http://handle.unsw.edu.au/1959.4/40537.

Full text

Abstract:

Relapsed ALL remams one of the most common causes of death from disease in children. Broad-range drug resistance is often associated with relapse, although its underlying molecular mechanisms remained poorly understood. The aim of this thesis was to establish an in vivo model using the non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse strain, to facilitate the engraftment, expansion and characterisation of childhood ALL cells, obtained from patients at diagnosis or relapse. Mice were inoculated with leukaemia cells from patients' biopsies and engraftment was monitored by the

APA, Harvard, Vancouver, ISO, and other styles

8

Fordham, Sarah Elizabeth. "DNA mismatch repair and cellular response to cytarabine : implications for the pathogenesis and treatment of therapy-related acute myeloid leukaemia." Thesis, University of Newcastle Upon Tyne, 2011. http://hdl.handle.net/10443/1366.

Full text

Abstract:

The DNA mismatch repair (MMR) pathway is responsible for correction of replicative errors, hence is a key factor in maintenance of genomic stability. Paradoxically, functional DNA MMR also mediates the cytotoxicity of certain chemotherapeutic DNA damaging agents. Poor treatment response in therapy-related acute myeloid leukaemia (t-AML) is influenced by a number of factors, one of which might be chemoresistance due to acquired defects in DNA MMR. Using a range of paired MMR proficient and deficient cell lines, investigations herein demonstrate that DNA MMR status mediates response to nucleosid

APA, Harvard, Vancouver, ISO, and other styles

9

Burrett, Julie Ann. "Identification of randomized trials for inclusion in meta-analyses of treatments for childhood acute lymphoblastic leukaemia, and investigation of factors leading to publication bias." Thesis, Open University, 2003. http://oro.open.ac.uk/22376/.

Full text

Abstract:

<b><u>Purpose</u></b>: Some randomized trials are reported widely, while others remain unpublished. It is essential to systematic reviewers and meta-analysts that factors leading to publication bias in the form of delayed or non-publication of an eligible study are identified. This thesis is an attempt to do this. <br></br><br></br> <b><u>Data</u></b>: The set of randomized trials identified by the Childhood Acute Lymphoblastic Leukaemia (ALL) Collaborative Group was used. This consists of 149 trials comprising 243 randomized comparisons (randomizations), starting prior to 1 January 1988, repo

APA, Harvard, Vancouver, ISO, and other styles

10

"Daunorubicin kinetics and drug resistance in leukaemia." Thesis, University of Technology, Sydney. Faculty of Science, 1996. http://hdl.handle.net/10453/20146.

Full text

Abstract:

University of Technology, Sydney. Faculty of Science.<br>The aims of this thesis were to examine: (1) plasma and cellular pharmacokinetics of daunorubicin and its major metabolite daunorubicinol in patients with acute leukaemia, and the relationships between pharmacokinetics, patient response and the presence of P glycoprotein; (2) actions of the multidrug resistance reversing agents cyclosporin A and trifluoperazine, at clinically achievable concentrations, on daunorubicin accumulation and retention in human leukaemia cell lines and patients with acute leukaemia; and (3) effect of daunorubici

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Acute Leukaemia - Treatment"

1

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Rooney, Maria Anne. An evaluation of the immune competence of children with common Acute Lymphoblastic Leukaemia, both during and post-treatment, by an investigation of the Lymphocyte sub-populations using monoclonal antibodies and the Alkaline Phosphatase Anti-Alkaline Phosphatase technique. [s.1: The Author], 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mendez, Irvin. Acute Myeloid Leukaemia: Symptoms, Diagnosis and Treatment. Nova Science Publishers, Incorporated, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

M, Carella Angelo, ed. Chronic myeloid leukaemia: Biology and treatment. London: Martin Dunitz, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Goldman, John M., Angelo M. Carella, George Q. Daley, Connie J. Eaves, and Hehlmann Rudiger. Chronic Myeloid Leukaemia: Biology and Treatment. Taylor & Francis Group, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

McCann, Shaun R. Leukaemia. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0007.

Full text

Abstract:

The word leukaemia still is associated with foreboding and a fear of premature death. Steady advances have been made in the treatment of childhood leukaemia but, with notable exceptions, the same is not true in adults. The so-called genetic/molecular revolution has extended the understanding of the pathogenesis of many forms of leukaemia but, as yet, has rarely facilitated cure. With the introduction of tyrosine kinase inhibitor therapy, chronic myeloid leukaemia is the obvious exception but it still needs to be seen as to whether the cytogenetic/molecular revolution can provide cures for many

APA, Harvard, Vancouver, ISO, and other styles

8

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Full text

Abstract:

Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presen

APA, Harvard, Vancouver, ISO, and other styles

9

Cutter, David, and Martin Scott-Brown. Treatment of cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0325.

Full text

Abstract:

The variety of conditions that are considered to be ‘cancer’ is extremely wide, with marked variation in the management approach from disease to disease. A common feature in the management of malignant conditions, however, is the involvement of a wide range of medical professionals at different stages of the patient pathway. This commonly includes physicians, surgeons, radiologists, pathologists, medical oncologists, radiation oncologists, and specialist nurses, as well as a plethora of other allied disciplines. As such, a practice that has been widely adopted is to work as a multidisciplinary

APA, Harvard, Vancouver, ISO, and other styles

10

McCann, Shaun R. Molecules, genes, and gene therapy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0009.

Full text

Abstract:

The twenty-first century has brought many innovations in haematology, with improved diagnostic technology, which may inform treatment choices for malignant diseases, and a better understanding of the genetics and/or epigenetics underlying many diseases. Unfortunately, the aetiology of most of these diseases still eludes us, and some common diseases such as sickle cell disease await simple, inexpensive, and widely available curative treatment. For reasons that are often obscure, some diseases have become fashionable and attract large research financial backing, whereas some do not. With the adv

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Acute Leukaemia - Treatment"

1

Jacobs, P., L. Wood, and N. Novitzky. "Treatment of Adult Acute Lymphoblastic Leukaemia." In Acute Leukemias II, 428–31. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_79.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bader, Peter, Franco Locatelli, and Christina Peters. "Paediatric Acute Lymphoblastic Leukaemia (ALL)." In The EBMT/EHA CAR-T Cell Handbook, 57–59. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_10.

Full text

Abstract:

AbstractAcute lymphoblastic leukaemia (ALL) is the most frequent malignant disease in childhood and adolescence, with an annual incidence of approximately 3–4 cases per 100,000 children under 15 years of age. Multimodal chemotherapy forms the base of current ALL treatment. Based on excellent national and international collaboration in consecutive prospective, randomized clinical trials, the prognosis of childhood ALL has significantly improved over time. Currently, up to 90% of all paediatric patients with ALL will survive.

APA, Harvard, Vancouver, ISO, and other styles

3

Rees, J. K. H., R. Gray, and F. G. J. Hayhoe. "The Ninth British Medical Research Council Trial for the Treatment of Acute Myeloid Leukaemia." In Acute Leukemias, 35–37. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71213-5_6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ortega, J. J., G. Javier, and T. Olive. "Treatment of Standard- and High-Risk Childhood Acute Lymphoblastic Leukaemia with Two CNS Prophylaxis Regimens." In Acute Leukemias, 483–92. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71213-5_85.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Reizenstein, Peter. "The Use of Biological Response Modifiers in Acute Myeloid Leukaemia." In New Approaches to the Treatment of Leukemia, 79–86. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75484-5_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

McCulloch, E. A. "Biological Characteristics of Acute Myeloblastic Leukaemia Contributing to Management Strategy." In New Approaches to the Treatment of Leukemia, 87–116. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75484-5_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Davis, C. L., A. Z. S. Rohatiner, J. Amess, J. Lim, and T. A. Lister. "Treatment of Recurrent Acute Myelogenous Leukaemia at a Single Centre Over a 10-Year Period." In Acute Leukemias II, 339–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rohatiner, A. Z. S., R. Bassan, R. Battista, J. E. Kingston, J. Amess, M. Carter, A. M. Oza, et al. "High-Dose Cytosine Arabinoside in the Treatment of Acute Lymphoblastic Leukaemia." In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 437–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78350-0_78.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Barnett, M. J., J. E. Kingston, A. Miller, A. Z. S. Rohatiner, M. A. Horton, M. F. Greaves, J. S. Malpas, and T. A. Lister. "Treatment of Minimal Residual Disease in “Poor Risk” Acute Lymphoblastic Leukaemia with High-Dose Cytosine Arabinoside." In Minimal Residual Disease in Acute Leukemia 1986, 205–10. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4273-8_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Tobler, A., and H. P. Koeffler. "Differentiation inducers and their potential use in the treatment of acute myelogenous leukaemia." In Cancer Biology and Medicine, 163–81. Dordrecht: Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-009-0385-2_6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Acute Leukaemia - Treatment"

1

Guindo, P. Nieto, H. Mateo Carrasco, FD Fernandez Gines, and E. Molina Cuadrado. "CP-137 Economic analysis of azacitidine versus decitabine for the treatment of acute myeloid leukaemia." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Megías-Vericat, JE, P. Montesinos, MJ Herrero, V. Bosó, F. Moscardó, L. Rojas, D. Martínez-Cuadrón, SF Aliño, MA Sanz, and JL Poveda. "PKP-003 Influence of cytarabine metabolic pathway polymorphisms in effectiveness of acute myeloid leukaemia induction treatment." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.431.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Soliman, Ranin, Carl Heneghan, Nancy Bolous, Iman Sidhom, Sonia Ahmed, Nia Roberts, Jason Oke, and Alaa Elhaddad. "122 Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukaemia in children." In EBM Live. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ebm-2022-ebmlive.37.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Soliman, Ranin, Carl Heneghan, Nancy Bolous, Iman Sidhom, Sonia Ahmed, Nia Roberts, Jason Oke, and Alaa Elhaddad. "173 Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukaemia in children." In Preventing Overdiagnosis Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/bmjebm-2022-podabstracts.94.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Agraz-Doblas, A., C. Bueno, P. Schneider, C. Revilla, T. Moreno, P. Ballerini, M. Bardini, RW Stam, P. Menéndez, and I. Varela. "PO-315 The mutational and transcriptome landscape of infant B-cell acute lymphoblastic leukaemia: the INTERFANT treatment protocol experience." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.345.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lopez-Montero, E., A. Mosquera-Torre, M. Touris-Lores, B. Sanchez-Iglesias, B. Bernardez-Ferran, and MJ Lamas-Diaz. "PS-086 Adding low dose allopurinol as hepatoprotector to the maintenance treatment with mercaptopurine in children with acute lymphoblastic leukaemia." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.592.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Grey, HET, and A. Davidson. "G555(P) Does the type of steroid used in the treatment of acute lymphoblastic leukaemia in childhood influence adult weight?" In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference and exhibition, 13–15 May 2019, ICC, Birmingham, Paediatrics: pathways to a brighter future. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-rcpch.538.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Valencia, JC del Río, MRuiz de Villegas Garcia Pelayo, RTamayo Bermejo, and I. Muñoz Castillo. "4CPS-105 Blinatumomab for the treatment of the relapse b-precursor acute lymphoblastic leukaemia in a paediatric patient: a case report." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.196.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Huynh, T., D. Vidovic, C. Dean, K. Lee, I. Weaver, and P. Marcato. "PO-372 Investigating the epigenetic changes underlying combination treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.400.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Del Río Valencia, JC, C. Ortega De La Cruz, T. Chinchilla Alarcón, and I. Muñoz Castillo. "4CPS-113 Inotuzumab–ozogamizin for the treatment of relapse B precursor acute lymphoblastic leukaemia in an adult patient: a case report." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!